Interfant-21
Project data
Project financing: 9 617 561,70 PLN (including financing for UMED: 3 249 122 PLN), financed by the Medical Research Agency (ABM) - ABM/2022/1
Project description:
The primary objective of the study is to improve outcomes for patients aged ≤ 365 days with newly diagnosed KMT2Au rearrangement acute lymphoblastic leukaemia (ALL) by applying a series of non-randomised interventions to well-defined historical control groups.
Interfant-21 is an international, multicentre, open-label, non-randomised, national-level clinical trial being revisited at 16 Polish paediatric centres. The estimated number of patients to be recruited at the Polish centres is approximately 20 patients over three years, which should represent 5% of the total international target group.
Beneficiary
Consortium composed of:
Medical University of Silesia in Katowice (Leader)
Medical University of Lodz (Partner)
Medical University of Lublin (Partner)
Independent Public Clinical Hospital No. 1 of the Medical University of Silesia in Katowice (under Stanisław Szyszko name) (Partner)
Coordinating Principal Investigator, National Coordinator
prof. Tomasz Szczepański, MD, PhD
UMED Site Principal Investigator
prof. Wojciech Młynarski, MD, PhD